Different Durations of Dual Anti-platelet Therapy after Percutaneous Coronary Intervention with Drug-eluting Stents in Patients with Coronary Disease:A Systematic Review
XIE Cheng, DING Xiao-liang, MIAO Li-yan*
Department of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou 215006, China
Abstract��OBJECTIVE To evaluate the benefits and risks of different durations of dual anti-platelet therapy after percutaneous coronary intervention with drug-eluting stent in patients with coronary disease. METHODS PubMed, Embase, Cochrane Library, CBM, CNKI, VIP, Wanfang Data, Clinical Trials and ICTRP were searched for randomized controlled trials(RCTs) comparing different DAPT durations after PCI with DES in patients with coronary disease. Risk of bias was assessed with the tool recommended by Cochrane Collaboration. Network Meta-analysis was performed with WinBUGS 1.4.3 and STATA 12.0. RESULTS A total of 3 230 articles were found and 10 RCTs including 31 643 patients were systematically reviewed. Network Meta-analysis showed there was no significantly difference among the 6 different durations in the rates of stent thrombosis, myocardial infarction, all-cause mortality and major bleeding, except that the durations of 6 months [OR 10.56,95%CI(1.62, 9.17)] and 12 months [OR 4.05,95%CI(1.01, 11.46)]were different with 30 months in the rate of stent thrombosis. Ranking of cumulative probabilities showed that 30 months and 36 months of DAPT had the lowest risk of stent thrombosis and myocardial infarction, meanwhile duration of 3 months and 6 months had the lowest risk of all-cause mortality and major bleeding. CONCLUSION Clinicians should assess the risks of stent thrombosis and bleeding according to patient��s individual condition and determine the optimal duration of DAPT. It is considered feasible to appropriately extend the duration of DAPT in patients at lower bleeding risk.
CHINESE SOCIETY OF CARDIOLOGY. Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation[J]. Chin J Cardiol(�л���Ѫ�ܲ���־), 2010, 38(8):675-690.
[2]
HAMM C W, BASSAND J P, AGEWALL S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:the Task Force for the management of acute coronary syndromes(ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology(ESC)[J]. Eur Heart J, 2011, 32(23):2999-3054.
[3]
TASK FORCE ON THE MANAGEMENT OF ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION OF THE EUROPEAN SOCIETY OF CARDIOLOGY(ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation[J]. Eur Heart J, 2012, 33(20):2569-2619.
[4]
CHINESE SOCIETY OF CARDIOLOGY. Guidelines for the management of acute coronary syndromes in patients presenting without ST-segment elevation[J]. Chin J Cardiol(�л���Ѫ�ܲ���־), 2012, 40(5):353-367.
[5]
AMERICAN COLLEGE OF EMERGENCY PHYSICIANS, SOCIETY FOR CARDIOVASCULAR ANGIOGRAPHY AND INTERVENTIONS. 2013 ACCF/AHA Guideline for the management of ST-elevation myocardial infarction:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol, 2013, 61(4):78-140.
[6]
AMSTERDAM E A, WENGER N K, BRINDIS R G, et al. 2014 AHA/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol, 2014, 64(24):139-228.
[7]
WINDECKER S, KOLH P, ALFONSO F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization:the Task Force on Myocardial Revascularization of the European Society of Cardiology(ESC) and the European Association for Cardio-Thoracic Surgery(EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions(EAPCI)[J]. Eur Heart J, 2014, 35(37):2541-2619.
[8]
MEHTA S R, TANGUAY J F, EIKELBOOM J W, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes(CURRENT-OASIS 7):a randomised factorial trial[J]. Lancet, 2010, 376(9748):1233-1243.
[9]
METHA S R, YUSUF S, PETERS R J, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention:the PCI-CURE study[J]. Lancet, 2001, 358(9281):527-533.
[10]
MONTALESCOT G, WIVIOTT S D, BROUNWALD E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction(TRITON-TIMI 38):double-blind, randomised controlled trial[J]. Lancet, 2009, 373(9665):723-731.
[11]
STEG P G, JAMES S, HARRINGTON R A, et al. Ticagrelor versus clopidogrel in patients with ST-Elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention:a platelet inhibition and patient outcomes(PLATO) Trial Subgroup Analysis[J]. Circulation, 2010, 122(21):2131-2141.
[12]
WALLEENTIN L, BECKER R C, BUDAJ A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med, 2009, 361(11):1045-1057.
[13]
WIVIOTT S D, BROUNWALD E, ANGIOLILLO D J, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38[J]. Circulation, 2008, 118(16):1626-1636.
[14]
BULLUCK H, KWOK C S, RYDING A D, et al. Safety of short-term dual antiplatelet therapy after drug-eluting stents:an updated meta-analysis with direct and adjusted indirect comparison of randomized control trials[J]. Int J Cardiol, 2015, 15(181):331-339.
[15]
CASSESE S, BYRNE R A, TADA T, et al. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era:a meta-analysis of randomized trials[J]. Eur Heart J, 2012, 33(24):3078-3087.
[16]
El-HAYEK G, MESSERLI F, BANGALORE S, et al. Meta-analysis of randomized clinical trials comparing short-term versus long-term dual antiplatelet therapy following drug-eluting stents[J]. Am J Cardiol, 2014, 114(2):236-242.
[17]
KWOK C S, BULLUCK H, RYDING A D, et al. Benefits and harms of extending the duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stents:a meta-analysis[J]. Scientific World Journal, 2014:794078.
[18]
LIU M, CHEN J, HUANG D, et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation:a meta-analysis of 3 randomized controlled trials[J]. J Cardiovasc Pharmacol, 2014, 64(1):41-46.
[19]
PANDIT A, GIRI S, HAKIM F A, et al. Shorter(</=6 months) versus longer(>/=12 months) duration dual antiplatelet therapy after drug eluting stents:a meta-analysis of randomized clinical trials[J]. Catheter Cardiovasc Interv, 2015, 85(1):34-40.
[20]
VALGIMIGLI M, PARK S J, KIM H S, et al. Benefits and risks of long-term duration of dual antiplatelet therapy after drug-eluting stenting:a meta-analysis of randomized trials[J]. Int J Cardiol, 2013, 168(3):2579-2587.
[21]
SALANTI G, HIGGINS J P, ADES A E, et al. Evaluation of networks of randomized trials[J]. Stat Methods Med Res, 2008, 17(3):279-301.
[22]
CHAIMANI A, HIGGINS J P, MAVRIDIS D, et al. Graphical tools for network meta-analysis in STATA[J]. PLoS One, 2013, 8(10):e76654.
[23]
GWON H C, HAHN J Y, PARK K W, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents:the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting(EXCELLENT) randomized, multicenter study[J]. Circulation, 2012, 125(3):505-513.
[24]
VALGIMIGLI M, BORGHESI M, TEBALDI M, et al. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY(PRODIGY)[J]. Eur Heart J, 2013, 34(12):909-919.
[25]
KIM B K, HONG M K, SHIN D H, et al. A new strategy for discontinuation of dual antiplatelet therapy:the RESET Trial(REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)[J]. J Am Coll Cardiol, 2012, 60(15):1340-1348.
[26]
FERES F, COSTA R A, ABIZAID A, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents:the OPTIMIZE randomized trial[J]. JAMA, 2013, 310(23):2510-2522.
[27]
LEE C W, AHN J M, PARK D W, et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation:a randomized, controlled trial[J]. Circulation, 2014, 129(3):304-312.
[28]
COLLET J P, SILVAIN J, BARTHELEMY O, et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation(ARCTIC-Interruption):a randomised trial[J]. Lancet, 2014, 384(9954):1577-1585.
[29]
GILARD M, BARRAGAN P, NORYANI A A, et al. Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin:ITALIC, a randomized multicenter trial[J]. J Am Coll Cardiol, 2015, 65(8):777-786.
[30]
COLOMBO A, CHIEFFO A, FRASHERI A, et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy:the SECURITY Randomized Clinical Trial[J]. J Am Coll Cardiol, 2014, 64(20):2086-2097.
[31]
MAURI L, KEREIAKES D J, YEH R W, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents[J]. N Engl J Med, 2014, 371(23):2155-2166.
[32]
SCHULZ-SCHUPKE S, BYRNE R A, TEN BERG J M, et al. ISAR-SAFE:a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting[J]. Eur Heart J, 2015, 36(20):1252-1263.
[33]
KASTRATI A, DIBRA A, SPAULDING C, et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction[J]. Eur Heart J, 2007, 28(22):2706-2713.
[34]
MCFADDEN E P, STABILE E, REGAR E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy[J]. Lancet, 2004, 364(9444):1519-1521.
[35]
ONG A T, MCFADDEN E P, REGAR E, et al. Late angiographic stent thrombosis(LAST) events with drug-eluting stents[J]. J Am Coll Cardiol, 2005, 45(12):2088-2092.
[36]
AIROLDI F, COLOMBO A, MORICI N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment[J]. Circulation, 2007, 116(7):745-754.
[37]
RABER L, MAGRO M, STEFANINI G G, et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents:a prospective cohort study[J]. Circulation, 2012, 125(9):1110-1121.
[38]
STEFANINI G G, BYRNE R A, SERRUYS P W, et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention:a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials[J]. Eur Heart J, 2012, 33(10):1214-1222.
[39]
IAKOVOU I, SCHMIDT T, BONIZZONI E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents[J]. JAMA, 2005, 293(17):2126-2130.
[40]
BERGER P B, BHATT D L, FUSTER V, et al. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease:results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance(CHARISMA) trial[J]. Circulation, 2010, 121(23):2575-2583.
[41]
BOWRY A D, BROOKHART M A, CHOUDHRY N K. Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events[J]. Am J Cardiol, 2008, 101(7):960-966.
[42]
DOYLE B J, RIHAL C S, GASTINEAU D A, et al. Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention:implications for contemporary practice[J]. J Am Coll Cardiol, 2009, 53(22):2019-2027.
[43]
IWATA Y, KOBAYASHI Y, FUKUSHIMA K, et al. Incidence of premature discontinuation of antiplatelet therapy after sirolimus-eluting stent implantation[J]. Circ J, 2008, 72(2):340-341.
[44]
GARG P, GALPER B Z, COHEN D J, et al. Balancing the risks of bleeding and stent thrombosis:a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents[J]. Am Heart J, 2015, 169(2):222-233.
2016, Vol. 51 
